Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro

2010 ◽  
Vol 15 (8) ◽  
pp. 1151-1159 ◽  
Author(s):  
Larisa V Gubareva ◽  
A Angelica Trujillo ◽  
Margaret Okomo-Adhiambo ◽  
Vasiliy P Mishin ◽  
Varough M Deyde ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Drug Susceptibility ◽  
Comprehensive Assessment ◽  
Influenza A H1n1

scholarly journals Highly Sensitive in Vitro Diagnostic System of Pandemic Influenza A (H1N1) Virus Infection with Specific MicroRNA as a Biomarker

ACS Omega ◽  
2019 ◽  
Vol 4 (11) ◽  
pp. 14560-14568 ◽  
Author(s):  
Jaewoo Lim ◽  
Jihyun Byun ◽  
Kyeonghye Guk ◽  
Seul Gee Hwang ◽  
Pan Kee Bae ◽  
...  
Keyword(s):  
Virus Infection ◽  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Diagnostic System ◽  
Highly Sensitive ◽  
Influenza A H1n1 ◽  
In Vitro Diagnostic ◽  
H1n1 Virus Infection

In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus

2013 ◽  
Vol 159 (6) ◽  
pp. 1279-1291 ◽  
Author(s):  
E. Bart Tarbet ◽  
Almut H. Vollmer ◽  
Brett L. Hurst ◽  
Dale L. Barnard ◽  
Yousuke Furuta ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Neuraminidase Inhibitor ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Influenza A H1n1

scholarly journals Virulence-Associated Substitution D222G in the Hemagglutinin of 2009 Pandemic Influenza A(H1N1) Virus Affects Receptor Binding

2010 ◽  
Vol 84 (22) ◽  
pp. 11802-11813 ◽  
Author(s):  
Salin Chutinimitkul ◽  
Sander Herfst ◽  
John Steel ◽  
Anice C. Lowen ◽  
Jianqiang Ye ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Severe Disease ◽  
Dynamics Modeling ◽  
Receptor Specificity ◽  
Influenza A H1n1 ◽  
Antigenic Properties

ABSTRACT The clinical impact of the 2009 pandemic influenza A(H1N1) virus (pdmH1N1) has been relatively low. However, amino acid substitution D222G in the hemagglutinin of pdmH1N1 has been associated with cases of severe disease and fatalities. D222G was introduced in a prototype pdmH1N1 by reverse genetics, and the effect on virus receptor binding, replication, antigenic properties, and pathogenesis and transmission in animal models was investigated. pdmH1N1 with D222G caused ocular disease in mice without further indications of enhanced virulence in mice and ferrets. pdmH1N1 with D222G retained transmissibility via aerosols or respiratory droplets in ferrets and guinea pigs. The virus displayed changes in attachment to human respiratory tissues in vitro, in particular increased binding to macrophages and type II pneumocytes in the alveoli and to tracheal and bronchial submucosal glands. Virus attachment studies further indicated that pdmH1N1 with D222G acquired dual receptor specificity for complex α2,3- and α2,6-linked sialic acids. Molecular dynamics modeling of the hemagglutinin structure provided an explanation for the retention of α2,6 binding. Altered receptor specificity of the virus with D222G thus affected interaction with cells of the human lower respiratory tract, possibly explaining the observed association with enhanced disease in humans.

scholarly journals Assessment of Pandemic and Seasonal Influenza A (H1N1) Virus Susceptibility to Neuraminidase Inhibitors in Three Enzyme Activity Inhibition Assays

2010 ◽  
Vol 54 (9) ◽  
pp. 3671-3677 ◽  
Author(s):  
Ha T. Nguyen ◽  
Tiffany G. Sheu ◽  
Vasiliy P. Mishin ◽  
Alexander I. Klimov ◽  
Larisa V. Gubareva
Keyword(s):  
Enzyme Activity ◽  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Drug Susceptibility ◽  
Neuraminidase Inhibitors ◽  
Virus Infections ◽  
Drug Concentrations ◽  
Influenza A H1n1 ◽  
Pandemic Influenza H1n1

ABSTRACT The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the treatment and prophylaxis of 2009 pandemic influenza A (H1N1) virus infections. The proven potential of these viruses to acquire NAI resistance during treatment emphasizes the need to assess their NAI susceptibility. The 50% inhibitory concentrations (IC50s) are known to vary depending on the neuraminidase inhibition (NI) test used; however, few side-by-side comparisons of different NI assays have been done. In the present study, a panel of 11 isolates representing 2009 seasonal and pandemic influenza H1N1 viruses, including oseltamivir-resistant H275Y variants, were tested in three functional NI assays: chemiluminescent (CL), fluorescent (FL), and colorimetric (CM). The sensitivities of the viruses to zanamivir, oseltamivir, and three investigational NAIs (peramivir, R-125489, and A-315675) were assessed. All isolates with the exception of H275Y variants were sensitive to all five NAIs by all three NI assays. The H275Y variants showed substantially elevated IC50s against oseltamivir and peramivir. The three NI assays generally yielded consistent results; thus, the choice of NI assay does not appear to affect conclusions based on drug susceptibility surveillance. Each assay, however, offers certain advantages compared to the others: the CL assay required less virus volume and the FL assay provided the greatest difference in the IC50s between the wild type and the variants, whereas the IC50s obtained from the CM assay may be the most predictive of the drug concentrations needed to inhibit enzyme activity in humans. It would be desirable to develop an NI assay which combines the advantages of all three currently available assays but which lacks their shortcomings.

scholarly journals Ultrastructural and Histopathological Studies of 2009 Pandemic Influenza A (H1N1) Virus

2010 ◽  
Vol 16 (S2) ◽  
pp. 1122-1123
Author(s):  
CS Goldsmith ◽  
MG Metcalfe ◽  
W-J Shieh ◽  
DM Blau ◽  
DC Rollin ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Influenza A H1n1 ◽  
Histopathological Studies

Extended abstract of a paper presented at Microscopy and Microanalysis 2010 in Portland, Oregon, USA, August 1 – August 5, 2010.

scholarly journals Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010

2013 ◽  
Vol 19 (3) ◽  
Author(s):  
Rebekah H. Borse ◽  
Sundar S. Shrestha ◽  
Anthony E. Fiore ◽  
Charisma Y. Atkins ◽  
James A. Singleton ◽  
...  
Keyword(s):  
United States ◽  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Influenza A H1n1

scholarly journals Influenza-Like Illness in a Community Surrounding a School-Based Outbreak of 2009 Pandemic Influenza A (H1N1) Virus-Chicago, Illinois, 2009

2010 ◽  
Vol 52 (Supplement 1) ◽  
pp. S94-S101 ◽  
Author(s):  
K. B. Janusz ◽  
J. E. Cortes ◽  
F. Serdarevic ◽  
R. C. Jones ◽  
J. D. Jones ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Influenza Like Illness ◽  
School Based ◽  
Influenza A H1n1

scholarly journals High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009

2010 ◽  
Vol 15 (31) ◽  
Author(s):  
K Waalen ◽  
A Kilander ◽  
S G Dudman ◽  
G H Krogh ◽  
T Aune ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Vaccination Campaign ◽  
Age Group ◽  
Norwegian Population ◽  
Influenza A H1n1 ◽  
High Prevalence ◽  
Substantial Rise ◽  
Epidemic Wave

The prevalence of antibodies reactive to the 2009 pandemic influenza A(H1N1) was determined in sera collected before the start of the pandemic, during the early phase, and after the main epidemic wave and nationwide vaccination campaign in Norway. A substantial rise in prevalence of antibodies at protective titres, from 3.2% to 44.9%, was observed between August 2009 and January 2010. The highest prevalence, 65.3%, was seen in the age group of 10-19 year-olds.

Sign in / Sign up

Export Citation Format

Share Document